Anika Therapeutics (ANIK) Tops Q2 EPS by 40c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.42, $0.40 better than the analyst estimate of $0.02. Revenue for the quarter came in at $32.6 million versus the consensus estimate of $29.21 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Jefferies Downgrades Alfen (ALFEN:NA) (ALFNF) to Hold
- KeyBanc Upgrades Innovage Holding Corp (INNV) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
